⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 25, 2024Journal of NeurologyOpen Access

United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use

Ali A. Habib Andrew J. Klink Srikanth Muppidi Anju Parthan S. Chloe Sader Alexandrina Balanean Ajeet Gajra Richard J. Nowak James F. Howard

View Full Paper

Ask AI

Bookmark

Share

Abstract

The phase 3 REGAIN study and its open-label extension demonstrated the efficacy of the complement C5 inhibitor eculizumab in patients with treatment-refractory, acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG). The aim of the ELEVATE study was to assess the effectiveness of eculizumab in clinical practice in adults with MG in the United States.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Habib et al. (2024) studied this question.

synapsesocial.com/papers/68e5f0a2b6db6435875852ed https://doi.org/10.1007/s00415-024-12569-w

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in ChinaCohort Study · 2026
2Case Report: Eculizumab in highly active myasthenia gravis complicated by severe infections2025 · 1 citations
3Improvement in Myasthenia Gravis Activities of Daily Living Subdomain Scores in Patients Treated with Eculizumab: Results from a Generalized Myasthenia Gravis Registry Study (P4-11.008)2024
4A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients2024 · 52 citations
5Effectiveness of Eculizumab Treatment by Time from Diagnosis in Patients with Generalized Myasthenia Gravis: A Retrospective Electronic Medical Record Analysis (S15.006)2024 · 1 citations